---
document_datetime: 2024-03-27 11:47:25
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/emgality-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: emgality-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 16.8017956
conversion_datetime: 2025-12-22 10:22:40.4118
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Emgality

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| N/0029               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                              | 25/03/2024                          |                                             | PL                               |           |
| IB/0027              | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation | 03/11/2023                          | n/a                                         |                                  |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| R/0023              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                             | 20/07/2023   | 01/09/2023   |                 |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-----------------|-----------------------------------|
| IB/0026             | B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                         | 14/07/2023   | n/a          |                 |                                   |
| IB/0025             | B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                         | 29/06/2023   | n/a          |                 |                                   |
| PSUSA/10733 /202209 | Periodic Safety Update EU Single assessment - galcanezumab                                                                                                                                                                                                                                                                          | 14/04/2023   | n/a          |                 | PRAC Recommendation - maintenance |
| IA/0024             | B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier                                                                                                                                                                                          | 13/02/2023   | n/a          |                 |                                   |
| IG/1565             | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                    | 06/12/2022   | n/a          |                 |                                   |
| IAIN/0020/G         | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.1.a - Replacement or addition of a | 11/11/2022   | 01/09/2023   | Annex II and PL |                                   |

<div style=\"page-break-after: always\"></div>

|                     | manufacturing site for the FP - Secondary packaging site A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                 |            |            |             |                                                                                                                                            |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10733 /202109 | Periodic Safety Update EU Single assessment - galcanezumab                                                                                                                                                                             | 19/05/2022 | 15/07/2022 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10733/202109. |
| IA/0019             | B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier                                                                                             | 14/06/2022 | n/a        |             |                                                                                                                                            |
| PSUSA/10733 /202103 | Periodic Safety Update EU Single assessment - galcanezumab                                                                                                                                                                             | 28/10/2021 | n/a        |             | PRAC Recommendation - maintenance                                                                                                          |
| PSUSA/10733 /202009 | Periodic Safety Update EU Single assessment - galcanezumab                                                                                                                                                                             | 20/05/2021 | 16/07/2021 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10733/202009. |
| PSUSA/10733 /202003 | Periodic Safety Update EU Single assessment - galcanezumab                                                                                                                                                                             | 29/10/2020 | n/a        |             | PRAC Recommendation - maintenance                                                                                                          |
| IAIN/0015           | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 14/07/2020 | n/a        |             |                                                                                                                                            |
| II/0013             | B.II.b.4.c - Change in the batch size (including batch size ranges) of the finished product - The change requires assessment of the comparability of a                                                                                 | 18/06/2020 | n/a        |             |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                     | biological/immunological medicinal product or a new bioequivalence study                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |             |                                                                                                                                                                                  |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10733 /201909 | Periodic Safety Update EU Single assessment - galcanezumab                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 17/04/2020 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                |
| II/0009             | Update of sections 4.2 and 5.1 of the SmPC following final results from a CONQUER study (A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults with Treatment-Resistant Migraine; the Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity correct to Slovakian contact information in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 26/03/2020 | 07/01/2021 | SmPC and PL | The SmPC section 4.2 and 5.1 has been updated to reflect the results of the study conducted in patients with treatment resistant migraine. The PL have been updated accordingly. |
| N/0012              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                | 16/03/2020 | 07/01/2021 | PL          |                                                                                                                                                                                  |
| IA/0011             | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 20/01/2020 | 07/01/2021 | SmPC        |                                                                                                                                                                                  |
| PSUSA/10733 /201903 | Periodic Safety Update EU Single assessment - galcanezumab                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 17/10/2019 | 09/12/2019 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10733/201903.                                       |
| IB/0008             | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                                                | 07/08/2019 | n/a        |             |                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| IB/0007/G   | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch takes place   | 31/07/2019   | n/a        |                        | control/testing   |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-------------------|
| IA/0006     | B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method                                                                                                                                                                      | 16/07/2019   | n/a        |                        |                   |
| IAIN/0003   | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                         | 08/02/2019   | n/a        |                        |                   |
| IAIN/0002   | B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes                                                                                                                                                                                         | 18/12/2018   | 09/12/2019 | SmPC, Labelling and PL |                   |
| IAIN/0001   | B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes                                                                                                                                                                                         | 18/12/2018   | 09/12/2019 | SmPC, Labelling and PL |                   |

<div style=\"page-break-after: always\"></div>